Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

The Endgame Scenarios for Sanofi-Genzyme
WSJ Online
Monday, October 4, 2010 - 5:16pm
tags:
Sanofi, hostile bid, Genzyme, M&A
Cypress Would Rather Sell to Anyone Besides Ramius
HedgeFund.net
Monday, October 4, 2010 - 11:54am
tags:
Ramius, Cypress Bioscience
Par Pharmaceutical: The Winning Streak Continues (PRX)
Comtex Smartrend
Monday, October 4, 2010 - 11:52am
tags:
Par Pharmaceutical
Sanofi’s Hostile Bid Triggered by Genzyme CEO’s Selective Deafness
BNET Pharma
Monday, October 4, 2010 - 11:38am
tags:
Genzyme, Henri Termeer, hostile bid, M&A, Sanofi
Sanofi chief plots course for booming cancer, diabetes markets
Fierce Biotech
Monday, October 4, 2010 - 11:26am
tags:
Sanofi, Pharma CEOs, cancer, diabetes, Chris Viehbacher
Arena Pharmaceuticals Investors Smell A Rat
Pharmalot
Monday, October 4, 2010 - 11:24am
tags:
Arena Pharmaceuticals, investors, Lorqess, obesity, FDA, advisory panels
Novo Nordisk to Invest $73m in Expansion of U.S. Manufacturing Facility
Yahoo
Monday, October 4, 2010 - 11:23am
tags:
Novo Nordisk, drug manufacturing
Genzyme advises shareholders not to act on bid
Marketwatch
Monday, October 4, 2010 - 11:22am
tags:
Genzyme, M&A, Sanofi, shareholders, hostile bid
Small study affirms Avastin as AMD treatment
Fierce Pharma
Monday, October 4, 2010 - 10:15am
tags:
Avastin, age-related macular degeneration, Roche, Lucentis, Genentech
Pfizer's Osteoarthritis Drug Runs Into Unique Roadblock
Seeking Alpha
Monday, October 4, 2010 - 10:14am
tags:
Pfizer, osteoarthritis, tanezumab
Teva Drug Approval Delayed
Yahoo/Zacks.com
Monday, October 4, 2010 - 10:11am
tags:
Teva Pharmaceuticals, Neutroval, biologics, BLA, FDA, febrile neutropenia
Endo's Latest Acquisition Builds Out Pain Franchise, Generics Lineup
Seeking Alpha
Monday, October 4, 2010 - 10:08am
tags:
generics, Endo, Qualitest, M&A, painkillers
Sanofi Likely to Shell out More for Genzyme: Analysts
CNBC
Monday, October 4, 2010 - 10:07am
tags:
analysts, Sanofi, M&A, hostile takeover, Genzyme
Drug stocks sluggish in early action
Marketwatch
Monday, October 4, 2010 - 10:03am
tags:
drug stocks
Read Sanofi’s $18.5 Billion Hostile Offer for Genzyme
WSJ Online
Monday, October 4, 2010 - 10:02am
tags:
hostile takeover, M&A, Sanofi, Genzyme
Antipsychotics, Illegal Marketing And Lawsuits
NY Times, NY
Monday, October 4, 2010 - 10:00am
tags:
lawsuits, antipsychotics, JNJ, AstraZeneca, Eli Lilly, Pfizer, Bristol-Myers Squibb
Johnson & Johnson: Strong Company At an Attractive Price, Part 2
Seeking Alpha
Monday, October 4, 2010 - 9:58am
tags:
JNJ
Johnson & Johnson: A Strong Company at an Attractive Price, Part 1
Seeking Alpha
Monday, October 4, 2010 - 9:57am
tags:
JNJ
Sanofi launches $18.5 bln hostile bid for Genzyme
Marketwatch
Monday, October 4, 2010 - 9:56am
tags:
M&A, Genzyme, Sanofi
Here We Go Again: Novartis Fined for Off-Label Marketing
Seeking Alpha
Sunday, October 3, 2010 - 12:22pm
tags:
Novartis, off label

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.